TRU Precious Metals Corp (TRU) Fair Value & Analysis
Healthcare · CA · Market cap A$13.7M
Fair value as of: Jun 26, 2026
From 3 valuation models · updated 3 days ago
Fair value updated Jun 26, 2026 — revised from A$0.0100 to A$0.0138 (+37.6%) since Jun 24, 2026. Share price −17.6% over the past month.
Price vs Fair Value (12 months)
12‑month range A$0.0120 – A$0.0190 · fair‑value band A$0.0129 – A$0.0146 · the A$0.0140 price screens above the A$0.0138 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TRU Precious Metals Corp (TRU) currently trades at A$0.0140, while our model-based Fair Value estimate is A$0.0138 — implying the stock looks roughly 1.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, TRU Precious Metals Corp generated revenue of A$2.8M at a net margin of -79.8%. Revenue grew 121.4% year over year. The balance sheet holds a net cash position of A$1.3M. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
TRU Precious Metals Corp. is involved in mineral exploration and development activities in Canada. The company explores for gold and copper deposits. Its flagship project includes 100% owned the Golden Rose project located in Central Newfoundland, Canada. The company was formerly known as Trius Investments Inc. and changed its name to TRU Precious Metals Corp. in October 2020. TRU Precious Metals Corp. was incorporated in 2021 and is headquartered in Fredericton, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TRU Precious Metals Corp reported revenue of A$2.5M in FY2025 versus A$2.5M in FY2021, a compound −1.0%/yr. Reported net income was −A$2.3M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | 1,600 MXN | 1,231 MXN | -23% |
| Stryker Corporation S1YK34 | R$77.83 | R$8.47 | -89% |
| Medtronic plc MDT | $80.25 | $74.40 | -7% |
| Boston Scientific Corporation B1SX34 | R$248.75 | R$221.81 | -11% |
| Edwards Lifesciences Corporation EW | $85.88 | $41.02 | -52% |
| Siemens Healthineers AG SEMHF | $40.29 | $47.96 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TRU Precious Metals Corp (TRU) undervalued?
What is the fair value of TRU?
What is the quality score of TRU?
What is the revenue of TRU Precious Metals Corp (TRU)?
What is the net profit margin of TRU?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.